Examination of the clinical efficacy of eribulin and trastuzumab in HER2‑positive recurrent breast cancer

Introduction

Estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-positive disease with metastatic breast cancer remain incurable (1–3). For metastatic breast cancer, anthracycline- and/or taxane-based chemotherapy is used as standard treatment (4); however, the outcome remains a common issue. Therefore, new treatments are required. The patients with overexpression of HER2 may benefit from trastuzumab, and these may perform more efficiently with chemotherapy regimens that contain anthracycline drugs. HER2 overexpression comprises 15–25% of all breast cancers (5). By contrast, vinca alkaloids, gemcitabine, capecitabine, liposomal anthracyclines and nanoparticle albumin-bound paclitaxel were approved as third-line or later treatment of metastatic breast cancer (6).

Eribulin maculate (E7389) is an analog of the natural marine product, halichondrin B, a nontaxane microtubule dynamics inhibitor extracted from the marine sponge Halichondria okadai, which inhibits microtubule structures via a novel mechanism of action (7). The drug induces an irreversible mitotic block, which leads to cell cycle arrest in the G2/M phase and apoptosis (8). It is distinguished mechanistically from other antimicrotubule agents, such as paclitaxel, ixabepilone and vinblastine (9). Additionally, the drug has potent antiproliferative effects against several different types of human cancer cell lines, including breast, prostate, melanoma and colorectal cancer (10,11), and has evolved activity against paclitaxel-resistant cell lines, including those with mutations in β-tubulin (12). It has also provided a manageable tolerability profile in phase I–II clinical trials and an improvement in overall survival compared with the treatment decided by the physician in a phase III trial (13).

In the present study, eribulin and trastuzumab were administered to 5 patients with recurrent breast cancer between October 2011 and August 2013. The study investigated eribulin and trastuzumab and reports the results obtained.

Patients and methods

Ethics statement

Only the demographic data of patients were stored in the database in the National Hospital Organization Kure Medical Center and Chugoku Cancer Center (Kure, Japan) to enable the retrieval of files manually based on patient codes. All the data were anonymously analysed without individual patient consent due to the retrospective nature of the study. The Review Board Ethics Committee waived the requirement for individual informed consent and approved the study (Approval Number 26–27, date 8/14/14).

Patients

Between October 2011 and August 2013, 5 patients with recurrent breast cancer were included in the study. All the patients received neoadjuvant or adjuvant taxane or antracycline chemotherapy following breast surgery. The mean age of the patients at the time of the eribulin and trastuzumab regimen administration was 70 years (range, 53–76 years) (Table I). The interval between tumor resection and local recurrence varied widely from 1.6 to 31.5 months. The histological type of the primary cancer was invasive ductal carcinoma in 5 patients. Pathological lymph node metastases at the time of surgery were classified as n1 in 2 patients, n2 in 1 and n3 in 2. Hormone sensitivity was identified as positive in 2 cases [1 case of ER+/progesterone receptor (PgR)+ and 1 case of ER−/PgR+] and negative in 3. Tamoxifen or aromatase inhibitors were postoperatively administered to all 5 patients.

Table I. Patient characteristics (n=5).

Table I.

Patient characteristics (n=5).

Characteristics	Patients
Age, median years (range)	70 (53–76)
Gender, n
Male	0
Female	5
Eastern Cooperative Oncology Group performance status, n (%)
0	5 (100)
≥1	0 (0)
Pathological lymph node metastases at the time of surgery, n (%)
n1	2 (40)
n2	1 (20)
n3	2 (40)
Hormone sensitivity, n (%)
ER+/PgR+	1 (20)
ER+/PgR−	0 (0)
ER−/PgR+	1 (20)
ER−/PgR−	3 (60)
American Joint Committee on Cancer stage, n (%)
IIIA	0 (0)
IIIB	1 (20)
IV	4 (80)
Metastases, n (%)
Lung	3 (60)
Liver	2 (40)
Bone	1 (20)
Brain	1 (20)
Supraclavicular lymph nodes	1 (20)
Infraclavicular lymph nodes	1 (20)
Mediastinal lymph nodes	1 (20)
Organs receiving treatment, n (%)
1	3 (60)
2	0 (0)
3	1 (20)
4	1 (20)
Treatment regimens prior to progression, median (range)	5 (5–11)
Type of prior treatment regimen, n (%)
Docetaxel/trastuzumab	4 (80)
Navelbine/trastuzumab	4 (80)
Capecitabine/trastuzumab	4 (80)
Trastuzumab alone	3 (60)
Paclitaxel/trastuzumab	2 (40)
Lapatinib/capecitabine	2 (40)
S1/trastuzumab	2 (40)
S1/lapatinib/capecitabine	2 (40)
Cyclophosphamide/lapatinib/capecitabine	2 (40)
Cyclophosphamide/capecitabine/trastuzumab	2 (40)
Toremifene/trastuzumab	2 (40)
S1/cyclophosphamide/trastuzumab	1 (20)
Gemcitabine/trastuzumab	1 (20)
Navelbine/gemcitabine/trastuzumab	1 (20)
Cyclophosphamide/trastuzumab	1 (20)
Anastrozole/trastuzumab	1 (20)

The status of pre-treatment ER and PgR was assessed by immunohistochemistry (IHC), and HER2 status was assessed by either fluorescent in situ hybridization or a validated IHC method, as previously described (14–16). Patients with HER2-receptor overexpression at the 3+ level (PATHWAY® HER2, clone 4B5; Ventana Medical Systems Inc., Tucson, AZ, USA) were immediately eligible for inclusion. When immunostaining was observed in >1% of tumor nuclei, the tumor was considered positive for the ER or PgR (16). Breast cancers were classified into five subtypes, as previously described (16).

The cancer stages in the 5 women who received this regimen were stage IIIB in 1 (20%) and stage IV in 4 (80%). The sites of recurrence were the lung in 3 patients, liver in 2, bone in 1, brain in 1, supraclavicular lymph nodes in 1, infraclavicular lymph nodes in 1 and mediastinal lymph nodes in 1. The median number of prior treatment regimens was 5 (range, 5–11).

Eribulin mesylate and trastuzumab were administered as previously described (15,17). Concomitant medication that did not interfere with the evaluation of eribulin could be administered, including antiemetics, antidiarrheal therapy, corticosteroids and antihistamines. Granulocyte colony-stimulating factor was allowed according to the American Society of Clinical Oncology guidelines and standard practice, including prophylactic use of growth factors (18).

Patients treated with bisphosphonates or denosumab at study entry could continue treatment. Other antitumor therapies were not allowed. This treatment cycle was repeated as long as the therapeutic effects were observed. The efficacy of eribulin and trastuzumab was assessed from the 2nd or 3rd cycle following administration according to the Response Evaluation Criteria in Solid Tumors guidelines (19).

Statistical analysis

Pearson χ2 tests were used to assess differences in overall response rates by group. All statistical analyses were performed using SPSS software, version 19.0 (IBM Corp., Tokyo, Japan). P=0.05 was considered to indicate a statistically significant difference.

Results

Patient variables

Among the 5 patients, 0 achieved complete response, 1 achieved partial response, 3 had stable disease, and 1 had progressive disease. The overall response rate was 20%, and the clinical benefit rate was 80%. The mean duration of eribulin and trastuzumab administration was 9 cycles (4–11). The status of hormone sensitivity did not affect the overall response rate (P=0.33, χ2).

Toxicities

All 5 patients were evaluated for toxicity using the Common Terminology Criteria for Adverse Events version 4.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40). Hematological toxicity was reversible and manageable. Patients reported grade 3/4 neutropenia (80.0%) (Table II). Although grade 4 neutropenia occurred, the patients were treated with granulocyte colony-stimulating factors. The most common grade 3/4 nonhematological toxicities were fatigue (20.0%), peripheral neuropathy (20.0%) and appetite loss (20.0%). There were no treatment-related fatalities. As these toxicities were mild, eribulin and trastuzumab dose omission was rare, and the study achieved favorable compliance.

Table II. All adverse events (n=5).

Table II.

All adverse events (n=5).

	Grades, n (%)
Adverse event	1	2	3	4
Anemia	1 (20)	2 (40)	0 (0)	0 (0)
Neutropenia	0 (0)	0 (0)	2 (40)	2 (40)
Nausea	3 (60)	0 (0)	0 (0)	0 (0)
Fatigue	2 (40)	1 (20)	1 (20)	0 (0)
Peripheral neuropathy	1 (20)	1 (20)	1 (20)	0 (0)
Gait disturbance	0 (0)	1 (20)	0 (0)	0 (0)
Appetite loss	2 (40)	0 (0)	1 (20)	0 (0)
Stomatitis	1 (20)	1 (20)	0 (0)	0 (0)
Diarrhea	2 (40)	0 (0)	0 (0)	0 (0)
Constipation	2 (40)	0 (0)	0 (0)	0 (0)

Discussion

The present study examined the efficacy of eribulin and trastuzumab in recurrent breast cancer. In a multicenter, phase II, single-arm study, 52 patients with recurrent or metastatic HER2-positive breast cancer received first-line eribulin with trastuzumab. The overall response rate was 71.2% with a median time to first response of 1.3 months; duration of response and progression free survival was 11.1 and 11.6 months, respectively (20). In the present study, the overall response rate was 20%, and the clinical benefit rate was 80%.

The toxicity profile was generally acceptable (Table II). The major toxicity was myelosuppression (the incidence of grade 3/4 toxicity was 80% for neutropenia), fatigue (the incidence of grade 3 was 20%), peripheral neuropathy (the incidence of grade 3 was 20%), and appetite loss (the incidence of grade 3 was 20%). Although grade 4 neutropenia occurred, the patients were treated with granulocyte colony-stimulating factors. Treatment-related fatalities were not observed. Consistent with this, the trial was reported by Wilks et al (20), who treated 52 patients with locally recurrent or metastatic HER2-positive breast cancer with eribulin and trastuzumab. The most common grade 3/4 treatment-emergent adverse events were neutropenia in 20 (38.5%) patients, peripheral neuropathy in 14 (26.9%; all grade 3), fatigue in 4 (7.7%) and febrile neutropenia in 4 (7.7%). Grade 3 adverse events included thrombocytopenia (in 28% of patients), fatigue (in 12%), peripheral neuropathy (in 12%) and neutropenia (in 11%), whereas grade 4 events (thrombocytopenia, neutropenia, vomiting, diarrhea and weakness) occurred in 14% of patients; otherwise, no severe adverse events occurred. The activity of eribulin with trastuzumab appears comparable with that of other combinations currently recommended for metastatic HER2-positive breast cancer (13). Although incidence rates vary, peripheral neuropathy is a common adverse event in patients treated with microtubule-targeted agents occurring in <30% of patients (21). Peripheral neuropathy grade 3/4 also occurs frequently in patients treated with eribulin. In the phase 3 EMBRACE trial, 35% of eribulin-treated patients had neuropathy, however, <9% had grade 3/4 neuropathy (13). Wilks et al (20) recently reported that 36 (69.2%) patients experienced neuropathy, and 14 (26.9%) experienced grade 3 neuropathy; no grade 4 neuropathy was observed. This higher rate of grade 3 neuropathy was likely due to the prolonged duration of eribulin treatment in this first-line setting.

In conclusion, recent clinical studies and the present study demonstrate that due to the high clinical benefit rate and acceptable safety profile, a combination of eribulin/trastuzumab is an acceptable treatment option for metastatic HER2-positive breast cancer. This may be a reflection of inadequate sample size. The present study is a retrospective study, and therefore, these results should be confirmed in further prospective studies.

Acknowledgements

The authors would like to thank Mrs. Kanako Tanaka for her excellent research assistance.

Glossary

Abbreviations

Abbreviations:

References